Scotia Capital Inc. Acquires 8,735 Shares of Sanofi (NASDAQ:SNY) (2024)

Scotia Capital Inc. grew its position in Sanofi (NASDAQ:SNY – Free Report) by 186.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,411 shares of the company’s stock after purchasing an additional 8,735 shares during the period. Scotia Capital Inc.’s holdings in Sanofi were worth $667,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Manhattan West Asset Management LLC boosted its stake in shares of Sanofi by 57.6% in the 4th quarter. Manhattan West Asset Management LLC now owns 67,928 shares of the company’s stock valued at $3,378,000 after purchasing an additional 24,817 shares in the last quarter. Catalytic Wealth RIA LLC acquired a new stake in shares of Sanofi in the 4th quarter valued at $346,000. Johnson Financial Group Inc. acquired a new position in Sanofi during the 4th quarter worth about $31,000. Congress Wealth Management LLC DE acquired a new position in Sanofi during the 4th quarter worth about $226,000. Finally, ProVise Management Group LLC lifted its position in Sanofi by 5.6% during the 4th quarter. ProVise Management Group LLC now owns 161,032 shares of the company’s stock worth $8,008,000 after buying an additional 8,554 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $49.21 on Wednesday. The stock has a market capitalization of $124.49 billion, a P/E ratio of 24.73, a P/E/G ratio of 1.54 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $55.72. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $48.29 and a two-hundred day moving average price of $48.39.

Sanofi (NASDAQ:SNY – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $0.96 earnings per share for the quarter, hitting the consensus estimate of $0.96. The firm had revenue of $11.36 billion during the quarter, compared to analysts’ expectations of $11.75 billion. Sanofi had a return on equity of 26.25% and a net margin of 10.52%. Equities analysts predict that Sanofi will post 4.11 earnings per share for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date is Thursday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. Sanofi’s dividend payout ratio is 74.37%.

Analyst Ratings Changes

SNY has been the topic of several research reports. TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Read Our Latest Report on Sanofi

Sanofi Company Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

See Also

• Five stocks we like better than Sanofi
• Using the MarketBeat Dividend Yield Calculator
• GitLab’s Weak Results Were Priced In; Time to Buy the Dip?
• Using the MarketBeat Stock Split Calculator
• Birkenstock Looks Like a Fit in Any Growth-Oriented Portfolio
• What is an Earnings Surprise?
• These Are the Most Active Congressional Trades This Quarter

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.